SARS-CoV-2 Infection and Chronic Demyelinating Inflammatory Polyradiculoneuropathy (CDIP)

Author: John Murphy, CEO The COVID-19 Long haul Foundation

Abstract

Objective

To examine the evidence linking infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to chronic demyelinating inflammatory polyradiculoneuropathy (CDIP), with particular attention to causation, immunopathogenesis, viral and host genomics, clinical phenotype, diagnostic evaluation, differential diagnosis, treatment, emerging therapies, and long-term prognosis.

Design

Narrative review of clinical, pathological, electrophysiological, immunological, genomic and therapeutic literature concerning SARS-CoV-2 infection, post-COVID neurological disease and CIDP. Particular weight was given to international CIDP diagnostic and treatment guidelines, systematic reviews, cohort studies, mechanistic investigations and published cases of CIDP temporally associated with SARS-CoV-2 infection.

Results

SARS-CoV-2 is a positive-sense, single-stranded RNA coronavirus whose approximately 30-kb genome encodes replication machinery, structural proteins and accessory proteins. Infection can produce neurological disease through several potentially overlapping mechanisms, including systemic inflammation, endothelial and microvascular injury, complement activation, dysregulated innate and adaptive immunity, molecular mimicry, autoantibody generation, altered blood-nerve-barrier integrity and, in a subset of patients, persistence of viral RNA, proteins or antigenic remnants. CIDP is an acquired immune-mediated disorder of peripheral nerves and roots characterized by chronic or relapsing motor and sensory dysfunction accompanied by electrophysiological evidence of demyelination. The biological plausibility of SARS-CoV-2 as a precipitating immune stimulus is therefore considerable, but the epidemiological evidence establishing SARS-CoV-2 as a direct cause of CIDP remains limited.

Published cases have demonstrated new-onset CIDP or acute-onset CIDP after COVID-19, including patients initially classified as having Guillain-Barré syndrome (GBS) who subsequently developed relapses beyond the temporal boundaries expected for GBS. Nevertheless, temporal association alone cannot establish causation. The differential diagnosis remains broad and includes GBS and treatment-related fluctuations, diabetic polyneuropathy, hereditary demyelinating neuropathies, anti-myelin-associated glycoprotein neuropathy, autoimmune nodopathy, paraproteinaemic neuropathies, vasculitic neuropathy, amyloidosis, nutritional deficiency, toxic neuropathy, motor neuron disease and structural spinal disease.

Diagnosis requires integration of phenotype, neurological examination, nerve-conduction studies/electromyography and exclusion of alternative causes. Cerebrospinal-fluid protein elevation, nerve-root or peripheral-nerve enlargement on MRI or ultrasound, and objective treatment response are supportive rather than pathognomonic findings. The 2021 European Academy of Neurology/Peripheral Nerve Society criteria distinguish typical CIDP from defined variants and emphasise electrodiagnostic evidence of demyelination. IV immunoglobulin, corticosteroids and plasma exchange remain established therapies. Subcutaneous immunoglobulin is an important maintenance treatment. More recently, FcRn blockade with efgartigimod has produced clinically meaningful reduction in relapse risk and represents a mechanistically important advance.

Conclusions

CIDP following SARS-CoV-2 infection is biologically plausible and clinically documented but should presently be regarded as a probable post-infectious immune-mediated association rather than a definitively proven direct viral complication. The principal clinical priority is accurate recognition of treatable inflammatory neuropathy while avoiding attribution of every post-COVID neuropathic symptom to CIDP. Future research should combine prospective longitudinal cohorts, standardized electrodiagnostic criteria, serological and pathological phenotyping, viral persistence studies, immunogenomics and controlled therapeutic trials.

Introduction

The neurological consequences of SARS-CoV-2 infection have evolved from an initially underappreciated component of COVID-19 to a major field of post-infectious medicine. During the acute phase of the pandemic, neurological manifestations were often interpreted as secondary consequences of systemic critical illness, hypoxaemia, thrombosis, metabolic disturbance or prolonged intensive-care treatment. Subsequent observation established that SARS-CoV-2 infection may also be followed by immune-mediated disorders involving both the central and peripheral nervous systems.[1-4]

Peripheral neuropathy occupies an especially important position within this spectrum because its manifestations are frequently subtle at onset, diagnostically heterogeneous and potentially disabling. Paresthesia, numbness, burning pain, impaired vibration, loss of proprioception, gait instability and weakness are all reported after COVID-19. Yet these symptoms constitute a clinical phenotype rather than a diagnosis. They may result from small-fiber neuropathy, large-fiber axonal neuropathy, autonomic dysfunction, radiculopathy, entrapment neuropathy, critical-illness neuropathy, diabetic neuropathy, medication toxicity or an immune-mediated demyelinating disorder.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is particularly important because it is potentially treatable and because delay in recognition may permit irreversible secondary axonal degeneration. CIDP classically produces progressive or relapsing weakness and sensory dysfunction involving proximal and distal limbs over at least eight weeks, usually accompanied by reduced or absent reflexes. Electrophysiological demonstration of demyelination remains central to diagnosis.[5-8]

The question addressed by this review is therefore more precise than whether COVID-19 “causes neuropathy.” The relevant question is whether SARS-CoV-2 infection can initiate, unmask or perpetuate the immune process responsible for CIDP, and, if so, by what mechanisms.

The distinction matters. Published reports of CIDP following SARS-CoV-2 infection are currently dominated by case reports and small series. A major review of peripheral nervous-system complications of COVID-19 identified CIDP among reported phenotypes but concluded that the available epidemiological and pathological evidence was insufficient to establish a causal relationship.[2] More recent individual reports have strengthened the clinical association, including reports of acute-onset CIDP after COVID-19 and of recurrent disease following infection.[9-11]

Accordingly, the appropriate scientific position is neither to dismiss the association nor to declare causation prematurely. SARS-CoV-2 can plausibly initiate an aberrant immune response directed against peripheral nerve structures; however, rigorous diagnosis of CIDP and rigorous attribution of causality must remain separate clinical exercises.

Methods

This article is a narrative synthesis of the literature concerning SARS-CoV-2 infection and CIDP. Searches were conducted using PubMed-indexed literature and major guideline and regulatory sources, with emphasis on publications addressing SARS-CoV-2 neuropathogenesis, peripheral neurological manifestations, CIDP diagnostic criteria, electrophysiology, immunopathology, differential diagnosis, treatment and long-term outcomes.

Particular attention was given to the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) guideline, subsequent validation studies, systematic reviews, randomized therapeutic trials and publications specifically describing CIDP after SARS-CoV-2 infection.[5-8,12]

Because the literature concerning post-COVID CIDP consists predominantly of case reports and observational studies, the strength of evidence supporting causation was graded qualitatively rather than by formal meta-analysis.

The terminology “CIDP” is used throughout. The requested term “CDIP” is presumed to refer to chronic inflammatory demyelinating polyradiculoneuropathy.

SARS-CoV-2: Virology and Genomic Architecture

SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus belonging to the Coronaviridae family. Its genome is approximately 29.9 kb and contains a large replicase region followed by genes encoding the structural proteins spike (S), envelope (E), membrane (M) and nucleocapsid (N), together with several accessory proteins.[13-15]

The 5′ genomic region contains ORF1a and ORF1b, which encode polyproteins subsequently cleaved into non-structural proteins forming the replication-transcription complex. Among these are the main protease, papain-like protease, RNA-dependent RNA polymerase, helicase and proofreading machinery. The structural S protein mediates cellular entry, whereas N packages genomic RNA and participates in viral replication and assembly.

The S protein consists principally of S1 and S2 functional regions. The receptor-binding domain within S1 interacts with angiotensin-converting enzyme 2 (ACE2), while proteolytic processing facilitates membrane fusion.[14,15] Neuropilin-1 and neuropilin-2 have also been implicated as accessory entry factors in some tissues.[3,16]

The genomic characteristics of SARS-CoV-2 are relevant to neurological disease for two reasons.

First, the virus continually evolves. Mutations in spike and other proteins alter transmissibility, receptor affinity, tissue tropism, antibody escape and potentially replication characteristics. The major waves of Alpha, Beta, Gamma, Delta and Omicron and their descendants demonstrated that SARS-CoV-2 is genetically dynamic.[13-15]

Second, genetic variation may influence the nature of host immune responses. Although direct evidence connecting a particular SARS-CoV-2 genotype to subsequent CIDP is presently absent, future studies could conceivably identify viral variants associated with greater propensity to post-infectious autoimmunity.

The relevant genomic question is therefore not simply whether SARS-CoV-2 contains a “neurological gene.” Rather, it is whether variation in viral proteins can influence the probability, intensity or duration of immune activation sufficiently to alter the risk of secondary neurological autoimmunity.

At present, this remains an important research hypothesis rather than an established clinical fact.

From Viral Infection to Peripheral Nerve Disease

Direct neuroinvasion versus immune-mediated injury

Three broad mechanisms can be considered.

The first is direct viral infection of neural or neural-associated cells. SARS-CoV-2 has been investigated for neurotropism, and ACE2, neuropilin and related entry machinery provide biological plausibility for interaction with neural tissues.[3,16] However, direct infection of peripheral nerves has not been established as the dominant mechanism of post-COVID demyelinating neuropathy.

The second is vascular and endothelial injury. SARS-CoV-2 infection can produce endothelial activation, complement deposition, platelet aggregation, microvascular injury and inflammatory vascular changes.[17] Because the peripheral nerve depends on an intricate microvascular network, disruption of endoneurial perfusion or the blood-nerve barrier could facilitate inflammatory injury.

The third, and arguably most relevant to CIDP, is immune dysregulation. A viral infection can activate antigen-presenting cells, T lymphocytes, B lymphocytes, complement and cytokine networks. In genetically susceptible individuals, this response may fail to terminate normally or may generate immune recognition of host antigens.

CIDP is itself considered an immune-mediated disease involving both cellular and humoral mechanisms. The peripheral nerve myelin, Schwann-cell-associated structures and nodes of Ranvier can become targets of inflammatory and antibody-mediated injury.[6,18]

Thus, SARS-CoV-2 need not invade the nerve directly to precipitate CIDP.

Etiological Models for Post-COVID CIDP

Molecular mimicry

Molecular mimicry proposes that microbial antigens resemble host structures sufficiently that an immune response directed against the pathogen cross-reacts with host tissue.

This mechanism has long been invoked in post-infectious neuropathies, particularly GBS. SARS-CoV-2 produces a large antigenic repertoire and can generate broad antibody responses. Whether a specific SARS-CoV-2 antigen consistently mimics a peripheral myelin or nodal antigen sufficiently to cause CIDP has not been established.

CIDP is probably more heterogeneous than GBS, and a single molecular mimicry model is unlikely to explain all cases.

B-cell activation and autoantibody formation

B-cell activation may be particularly relevant because certain CIDP phenotypes are associated with antibodies against nodal and paranodal proteins.

Antibodies against neurofascin-155, contactin-1 and related proteins identify subgroups with distinctive clinical and therapeutic characteristics. Some of these antibodies are predominantly IgG4 and may define autoimmune nodopathies rather than classical CIDP.[6,18]

This distinction is increasingly important. The modern CIDP spectrum is no longer regarded as a single homogeneous disease. Patients with autoimmune nodopathies may respond differently to conventional IVIg and corticosteroids and may require targeted B-cell-directed therapy.[6,18]

SARS-CoV-2 could theoretically trigger such antibodies in a susceptible host. However, systematic evidence demonstrating a higher prevalence of nodal autoantibodies among post-COVID CIDP patients remains lacking.

T-cell-mediated inflammation

T cells contribute to inflammatory peripheral nerve injury through antigen recognition, macrophage activation and cytokine signaling. Histopathological studies of CIDP have demonstrated inflammatory infiltrates, macrophage-mediated demyelination and segmental demyelination/remyelination.

COVID-19 can profoundly alter T-cell populations, including activation and exhaustion. Persistent immune abnormalities after infection have also been described in long COVID.[19-21]

A plausible model therefore involves initial antiviral T-cell activation followed by incomplete immune resolution and inappropriate targeting of peripheral nerve structures.

Complement

Complement activation is an important mediator of tissue injury in COVID-19. Neurovascular studies have demonstrated endothelial activation, complement deposition, platelet aggregation and microvascular pathology.[17]

Complement also participates in peripheral nerve injury and demyelination. Consequently, complement represents a plausible bridge between systemic SARS-CoV-2-associated inflammation and peripheral nerve damage.

Whether complement activation is merely an epiphenomenon or a central therapeutic target in post-COVID CIDP remains unresolved.

Blood-nerve-barrier disruption

The blood-nerve barrier normally restricts circulating immune components from the endoneurial compartment. Systemic inflammation and endothelial injury may increase permeability, permitting immunoglobulins, complement and activated leukocytes to reach vulnerable peripheral nerve structures.

A “two-hit” model is therefore conceivable:

SARS-CoV-2 produces systemic endothelial and immune activation.
Increased blood-nerve-barrier permeability permits or amplifies immune-mediated nerve injury.

This model would explain why the neuropathy can begin after the acute infection has apparently resolved.

Viral Persistence and Long COVID

One of the most consequential developments in post-COVID research has been recognition that some patients demonstrate persistent SARS-CoV-2 RNA, proteins or antigenic material in tissues after the acute illness.[19-22]

The precise significance of such findings remains debated. Detection of viral RNA or protein does not necessarily demonstrate replication-competent virus. Nevertheless, persistent antigen could theoretically provide continuing stimulation to the immune system.

A contemporary model of long COVID proposes interaction among viral persistence, immune dysregulation, endothelial dysfunction, altered coagulation, microbiome disturbance and autonomic or neurovascular abnormalities.[19-22]

If persistent viral antigen maintains chronic immune activation, several pathways could theoretically converge upon peripheral nerves:

sustained cytokine signaling;
chronic B-cell activation;
persistence of autoreactive B-cell clones;
complement activation;
endothelial dysfunction;
blood-nerve-barrier impairment;
microvascular ischemia;
altered Schwann-cell function;
mitochondrial and metabolic stress.

This model is attractive but must not be overstated. There is currently no evidence that persistent SARS-CoV-2 in peripheral nerves is a universal or necessary cause of CIDP.

Indeed, classical CIDP predates COVID-19 by decades and occurs in individuals without SARS-CoV-2 exposure. Post-COVID cases should therefore be viewed as a possible etiological subgroup rather than as a new disease.

CIDP: Definition and Disease Biology

CIDP is a chronic immune-mediated disorder affecting peripheral nerves and nerve roots. Typical CIDP produces relatively symmetric motor and sensory impairment involving both proximal and distal limbs and evolving over at least eight weeks.[5-8]

The disease is characterized electrophysiologically by acquired demyelination. Hallmark abnormalities include:

prolonged distal motor latencies;
reduced motor conduction velocities;
prolonged or absent F waves;
conduction block;
abnormal temporal dispersion;
prolonged or absent sensory responses;
prolonged motor latencies inconsistent with purely axonal disease.

The 2021 EAN/PNS guideline recognizes typical CIDP and several variants, including distal, multifocal/focal, motor and sensory forms.[5,6]

This distinction is not semantic. A patient with predominantly distal sensory ataxia and an IgM monoclonal gammopathy should not automatically be classified as having typical CIDP. Similarly, a patient with asymmetric motor neuropathy may have multifocal motor neuropathy rather than CIDP.

Pathology of CIDP

The classical pathological lesion is segmental demyelination with remyelination. Repeated cycles of demyelination and remyelination can produce concentric Schwann-cell proliferation, historically described as “onion bulbs.”

Macrophages can enter myelin sheaths and strip myelin from axons. Endoneurial and perivascular inflammatory changes may be present.

However, pathology is neither required nor uniquely diagnostic in most patients.

The disease can progress from demyelinating injury to secondary axonal loss. This distinction has major prognostic importance. Myelin can be regenerated relatively effectively; a severely injured axon is substantially less capable of complete regeneration, particularly in older patients or when motor neuron loss and prolonged denervation have occurred.

Thus, the principal therapeutic rationale for early treatment is not merely symptom reduction. It is prevention of irreversible axonal injury.[23]

Genomic and Host-Susceptibility Considerations

There is currently no established CIDP-specific genomic signature that predicts post-SARS-CoV-2 CIDP.

Nevertheless, host genetics almost certainly influence susceptibility to immune-mediated disease.

Potential mechanisms include variation in:

human leukocyte antigen presentation;
innate immune signaling;
interferon pathways;
complement regulation;
B-cell activation;
T-cell receptor repertoires;
Fc receptor biology;
cytokine signaling;
immune tolerance.

The intersection of viral and host genomics deserves substantially greater investigation.

A useful conceptual model is:

viral genotype × host immune genotype × previous immune history × age/comorbidity × infection severity → probability and phenotype of post-infectious autoimmunity.

Such a framework could explain why millions of people have experienced SARS-CoV-2 infection whereas only a small minority develop recognizable immune-mediated neuropathies.

At present, however, it would be premature to use SARS-CoV-2 genomic sequencing clinically to predict CIDP.

Clinical History and Physical Examination

The clinical history remains the cornerstone of diagnosis.

Temporal history

The clinician should establish:

date of SARS-CoV-2 infection;
method of diagnosis;
acute severity;
hospitalization;
antiviral treatment;
vaccination history;
interval between infection and neurological symptoms;
progression rate;
periods of improvement;
relapses;
preceding neurological symptoms;
previous neuropathy;
diabetes;
alcohol exposure;
nutritional deficiency;
malignancy;
monoclonal gammopathy;
autoimmune disease;
medications and toxins;
family history of neuropathy.

The temporal relationship is important but should never substitute for diagnostic evidence.

A neuropathy that begins three months after COVID-19 is not automatically CIDP. Conversely, a patient with unequivocal demyelinating electrophysiology and a compatible clinical phenotype should not be denied appropriate treatment merely because the latency from infection is long.

Motor symptoms

Patients may report:

difficulty climbing stairs;
inability to rise from a chair;
foot drop;
tripping;
difficulty opening jars;
loss of hand dexterity;
difficulty using pedals;
inability to walk on heels or toes;
progressive gait deterioration.

Proximal weakness is particularly characteristic of typical CIDP.

Sensory symptoms

These may include:

numbness;
tingling;
loss of vibration;
impaired joint-position sense;
sensory ataxia;
burning pain;
electric-shock sensations;
impaired temperature discrimination.

Large-fibre sensory loss, especially loss of vibration and proprioception, is particularly important because it can produce profound gait instability even when motor strength remains relatively preserved.

Reflexes

Diffuse hyporeflexia or areflexia is characteristic, although exceptions occur.

Cranial nerves

Cranial neuropathies can occur in immune-mediated neuropathies, but prominent cranial involvement should prompt consideration of alternative diagnoses or GBS-spectrum disease, particularly in an acute presentation.

Autonomic symptoms

Autonomic involvement is not the defining feature of CIDP. Marked autonomic dysfunction should therefore broaden the differential diagnosis.

Neurological Examination

A formal examination should include:

Mental status

Although not diagnostic of CIDP, cognition should be documented because post-COVID patients may have concurrent cognitive complaints.

Cranial nerves

Assess facial symmetry, eye movements, swallowing, tongue function and hearing.

Motor system

Document strength quantitatively using the Medical Research Council scale, preferably in a reproducible manner.

Important muscles include:

deltoids;
biceps;
triceps;
wrist extensors and flexors;
finger abductors;
hip flexors;
hip abductors;
knee extensors and flexors;
ankle dorsiflexors;
plantar flexors.

Sensory examination

Test:

pinprick;
temperature;
vibration;
joint position;
Romberg sign.

Reflexes

Record biceps, triceps, brachioradialis, patellar and Achilles reflexes.

Gait

Assess:

ordinary gait;
tandem gait;
heel walking;
toe walking;
turning;
ability to rise from a chair;
need for assistive devices.

Functional scales

Objective measures such as INCAT, I-RODS, MRC sum score and grip strength can establish baseline disability and quantify response to therapy.

Diagnostic Evaluation

Nerve-conduction studies and electromyography

Electrodiagnostic testing is the central objective investigation.

The study should include multiple motor and sensory nerves in both upper and lower limbs when clinically appropriate.

The goal is to demonstrate acquired demyelinating abnormalities while excluding common mimics.

The 2021 EAN/PNS framework emphasizes defined electrodiagnostic criteria rather than nonspecific slowing alone.[5,6]

This is crucial because reduced conduction velocity can occur for many reasons.

A diagnosis of CIDP should not be based simply on the phrase “demyelinating neuropathy” appearing on an EMG report.

Important electrophysiological findings

Demyelination is supported by combinations of:

marked prolongation of distal motor latency;
reduced motor conduction velocity;
prolonged F-wave latency;
conduction block;
temporal dispersion;
abnormal sensory conduction.

The abnormalities should be interpreted in anatomical distribution and in relation to technical factors such as temperature, age and entrapment sites.

Cerebrospinal Fluid

Lumbar puncture may demonstrate elevated CSF protein with a relatively normal cell count, the classic albuminocytological dissociation.

However, elevated CSF protein is not specific to CIDP.

Protein concentration can increase with age, diabetes, spinal stenosis and other neurological conditions. Marked pleocytosis should prompt consideration of infection, malignancy or inflammatory disease other than classical CIDP.

CSF therefore functions as a supportive rather than definitive investigation.

Magnetic Resonance Imaging

MRI of the spine may show enhancement or enlargement of nerve roots and the cauda equina.

Nerve-root enlargement is supportive of inflammatory demyelinating polyradiculoneuropathy but is not specific.

Recent evidence indicates that MRI assessment of peripheral nerve roots can contribute diagnostically, particularly in patients whose electrodiagnostic findings are borderline.[24]

MRI also has major value for excluding structural explanations such as:

spinal stenosis;
disc disease;
postoperative fibrosis;
tumor;
arachnoiditis;
compressive radiculopathy.

Peripheral Nerve Ultrasound

High-resolution nerve ultrasound is increasingly useful.

CIDP can produce enlargement of peripheral nerves and increased cross-sectional area, particularly at proximal segments and non-entrapment sites.

Ultrasound may be particularly valuable when differentiating CIDP from diabetic polyneuropathy, although it is not a stand-alone diagnostic test.[25]

The emergence of ultrasound illustrates a broader transformation in CIDP diagnosis: electrodiagnostic medicine is increasingly being complemented by structural neuroimaging.

Laboratory Testing

There is no single blood test that confirms CIDP.

The laboratory evaluation should instead search systematically for alternative or contributory causes.

A reasonable baseline panel includes:

complete blood count;
comprehensive metabolic profile;
fasting glucose;
HbA1c;
vitamin B12;
folate where appropriate;
thyroid-stimulating hormone;
serum protein electrophoresis;
serum immunofixation;
quantitative immunoglobulins;
serum free light chains;
ESR/CRP when inflammatory disease is suspected.

Additional tests should be guided by phenotype.

Potential investigations include:

ANA;
ANCA;
rheumatoid factor;
complement;
HIV;
hepatitis B;
hepatitis C;
Lyme testing where epidemiologically appropriate;
syphilis serology;
anti-MAG antibodies;
nodal/paranodal antibodies;
anti-ganglioside antibodies;
genetic testing;
cryoglobulins;
amyloidosis evaluation.

A monoclonal protein deserves particular attention. Paraproteinaemic neuropathies may mimic CIDP electrophysiologically while requiring entirely different treatment.[26,27]

Differential Diagnosis

Guillain-Barré syndrome

GBS is the most important acute differential diagnosis.

The distinction is primarily temporal and clinical.

GBS generally evolves rapidly, reaching nadir within four weeks. CIDP classically progresses over more than eight weeks.

The distinction becomes difficult in acute-onset CIDP.

A patient initially diagnosed with GBS who deteriorates repeatedly, particularly after eight weeks, should be reconsidered for A-CIDP.[28,29]

This distinction has direct therapeutic consequences because GBS and CIDP require different long-term treatment strategies.

Diabetic polyneuropathy

Diabetic distal symmetric polyneuropathy is common and may coexist with CIDP.

Diabetes can produce slowed nerve conduction and therefore falsely suggest demyelination.

CIDP should be considered when weakness is disproportionate to the expected diabetic neuropathy, particularly when there is prominent proximal weakness, diffuse areflexia, conduction block or convincing multifocal demyelination.[30]

Recent nerve-ultrasound studies suggest that combining clinical disability and nerve enlargement may improve discrimination between diabetic polyneuropathy and CIDP.[25]

Hereditary neuropathy

Charcot-Marie-Tooth disease and related inherited demyelinating neuropathies can resemble CIDP.

Clues include:

lifelong symptoms;
family history;
foot deformities;
unusually uniform slowing of conduction;
longstanding gait abnormality;
lack of objective response to immunotherapy.

A mistaken diagnosis can expose a patient to years of unnecessary immunosuppression.

Anti-MAG neuropathy

Anti-MAG neuropathy is typically associated with IgM monoclonal gammopathy and produces a slowly progressive distal sensory-predominant neuropathy, often with ataxia and tremor.[26]

Its electrophysiological findings may satisfy demyelinating criteria, making serum protein studies indispensable.

Autoimmune nodopathy

Patients with antibodies against neurofascin-155, contactin-1 or related nodal proteins may have severe sensory ataxia, tremor, distal weakness or poor response to conventional IVIg.

These patients may have a disease mechanism distinct from classical CIDP.

Multifocal motor neuropathy

Multifocal motor neuropathy produces asymmetric distal weakness, usually without substantial sensory impairment.

Conduction block outside common compression sites is characteristic.

IVIg is generally preferred; corticosteroids may be ineffective or harmful.

Vasculitic neuropathy

Vasculitic neuropathy often produces painful, asymmetric, stepwise deficits consistent with mononeuritis multiplex.

Inflammatory markers, autoimmune serology and occasionally nerve/muscle biopsy may be necessary.

Amyloidosis

Transthyretin and light-chain amyloidosis can produce neuropathy, frequently accompanied by autonomic dysfunction and systemic manifestations.

Because treatment is fundamentally different from CIDP therapy, recognition is essential.

Vitamin deficiency

Vitamin B12 deficiency can produce sensory ataxia and proprioceptive loss, sometimes with weakness.

Copper deficiency and other nutritional abnormalities should be considered in appropriate clinical circumstances.

Toxic neuropathy

Chemotherapeutic agents, excessive alcohol and various medications can produce predominantly axonal neuropathies.

Spinal disease

Cervical or lumbar spinal stenosis, radiculopathy, myelopathy and postoperative changes can coexist with peripheral neuropathy.

The presence of a significant spinal abnormality does not exclude CIDP, nor does CIDP explain every lower-extremity symptom in a patient with spinal disease.

CIDP in the Context of SARS-CoV-2 Infection

The strongest evidence for a relationship between COVID-19 and CIDP consists of temporally associated cases with clinical, electrophysiological and CSF findings compatible with inflammatory demyelination.

One report described acute-onset CIDP after SARS-CoV-2 infection, with initial improvement after IVIg followed by relapse and subsequent evolution into a chronic course.[9]

Another report described two cases of acute-onset CIDP occurring after SARS-CoV-2 infection or vaccination. The infection-associated case initially resembled GBS and subsequently relapsed beyond the expected time course, leading to a diagnosis of A-CIDP.[10]

A more recent case report described post-COVID CIDP in a young woman who developed persistent neurological symptoms following confirmed SARS-CoV-2 infection.[11]

These reports establish clinical possibility, but they do not establish population-level causation.

The problem is one of background incidence.

CIDP occurs spontaneously. SARS-CoV-2 infected hundreds of millions of people. Even an unrelated disease will inevitably occur after COVID-19 in a substantial number of individuals.

Causal inference therefore requires evidence exceeding temporal sequence.

A convincing epidemiological association would require:

increased incidence of CIDP after SARS-CoV-2 compared with appropriate controls;
consistent latency;
biological gradient where appropriate;
reproducibility across populations;
mechanistic evidence;
ideally, evidence that particular immune phenotypes are enriched after infection.

At present, these requirements are incompletely satisfied.

Does SARS-CoV-2 Cause CIDP or Trigger CIDP?

The most defensible model is that SARS-CoV-2 can trigger or unmask immune-mediated demyelinating neuropathy in susceptible individuals.

This wording is preferable to the assertion that SARS-CoV-2 directly infects peripheral nerves and causes CIDP.

Three categories of patients may exist.

De novo post-infectious CIDP

The patient has no preceding neuropathy and develops an objectively demonstrated inflammatory demyelinating neuropathy following COVID-19.

SARS-CoV-2-unmasked CIDP

The patient has subtle pre-existing disease that becomes clinically evident after infection.

Coincidental CIDP

CIDP begins after SARS-CoV-2 infection but is unrelated biologically to the infection.

Distinguishing these groups will require prospective studies.

Relationship to Long COVID

Long COVID and CIDP should not be conflated.

Long COVID is a multisystem syndrome encompassing fatigue, post-exertional symptom exacerbation, cognitive dysfunction, autonomic disturbance, respiratory symptoms, pain and numerous other manifestations.[19-22]

CIDP is a specific neurological disease defined by a particular clinical phenotype and objective electrophysiological evidence of acquired demyelination.

A patient with post-COVID numbness and fatigue does not have CIDP unless the diagnostic criteria are satisfied.

Conversely, a patient with confirmed CIDP should not have the disease dismissed as nonspecific long COVID.

This distinction is clinically consequential because CIDP has established disease-modifying therapies.

Treatment

Treatment should follow established CIDP principles regardless of whether SARS-CoV-2 preceded the disease.

There is presently no evidence that post-COVID CIDP requires an entirely different therapeutic algorithm.

Intravenous immunoglobulin

IVIg is a first-line therapy.

Its mechanisms are multifactorial and include:

Fc receptor modulation;
neutralization of pathogenic antibodies;
complement inhibition;
modulation of cytokine networks;
alteration of B-cell and T-cell activity;
suppression of inflammatory pathways.

Clinical trials have established efficacy in CIDP, and international guidelines recommend IVIg as a principal first-line treatment.[5,7,12]

The response may be rapid, but maintenance therapy may be necessary.

A critical clinical principle is that objective response should be documented rather than inferred solely from subjective impressions.

Corticosteroids

Corticosteroids remain a first-line option.

Potential regimens include daily oral therapy, pulsed dexamethasone or intermittent high-dose intravenous methylprednisolone, depending on patient characteristics and local practice.

Their principal disadvantages include:

hyperglycaemia;
hypertension;
osteoporosis;
infection risk;
cataracts;
weight gain;
mood disturbance;
myopathy;
adrenal suppression.

These risks are particularly relevant in older adults and in patients with diabetes.

Plasma Exchange

Plasma exchange is strongly supported as a treatment for CIDP that does not respond adequately to IVIg or corticosteroids.[5,7]

It can produce substantial improvement by removing circulating pathogenic immunoglobulins and other inflammatory mediators.

Its disadvantages include:

vascular access;
hypotension;
electrolyte disturbance;
bleeding;
infection;
logistical complexity.

Plasma exchange may be particularly useful in severe or refractory disease and in selected antibody-mediated neuropathies.

Subcutaneous Immunoglobulin

Subcutaneous immunoglobulin provides a valuable maintenance option for patients who respond to IVIg.

Advantages include:

home administration;
avoidance of venous access;
more stable immunoglobulin concentrations;
potentially greater independence.

It should generally be regarded as maintenance rather than rescue therapy.[5,7]

FcRn Blockade and Efgartigimod

One of the most important recent developments in CIDP therapy is FcRn blockade.

The neonatal Fc receptor (FcRn) protects IgG from lysosomal degradation and thereby prolongs its circulating half-life.

Blocking FcRn accelerates IgG catabolism.

Because pathogenic IgG antibodies contribute to several autoimmune diseases, lowering total IgG can reduce disease activity.

The ADHERE trial evaluated subcutaneous efgartigimod in adults with CIDP. Of 322 patients entering the initial treatment stage, 214 demonstrated predefined evidence of clinical improvement. Among responders subsequently randomized to withdrawal, efgartigimod significantly reduced relapse risk compared with placebo, with a hazard ratio of 0.39.[31]

The trial therefore provides high-quality evidence that targeted reduction of circulating IgG can alter the course of CIDP.

The US Food and Drug Administration subsequently approved efgartigimod alfa/hyaluronidase-qvfc for adults with CIDP.[32]

This development has implications extending beyond treatment. It strengthens the concept that pathogenic IgG is biologically important in at least a substantial subgroup of CIDP.

Whether FcRn blockade is especially effective in post-COVID CIDP remains unknown.

Rituximab and B-cell-directed Therapy

Rituximab, an anti-CD20 monoclonal antibody, has been used in refractory CIDP and in antibody-associated nodopathies.

The strongest rationale occurs when a disease phenotype suggests pathogenic B-cell or antibody production.

Evidence is less robust than for IVIg, corticosteroids, plasma exchange and efgartigimod.

In autoimmune nodopathy, however, B-cell-directed treatment may prove particularly valuable.

Other Immunosuppressive Agents

Agents that have been used in refractory CIDP include:

azathioprine;
mycophenolate mofetil;
cyclophosphamide;
cyclosporine;
methotrexate;
rituximab.

Evidence is heterogeneous, and these therapies should generally be reserved for selected patients under specialist supervision.

Treatment should be individualized according to phenotype, comorbidity, severity, previous treatment response and adverse-effect profile.

Symptomatic Management

Disease modification is only one component of care.

Patients may require:

neuropathic pain treatment;
physical therapy;
occupational therapy;
gait training;
orthoses;
fall prevention;
assistive devices;
home modifications;
speech and swallowing assessment when indicated;
psychological support;
sleep management.

Rehabilitation is particularly important after prolonged weakness because neurological recovery can lag behind immunological control.

Why Treatment Response Must Be Measured Objectively

A common diagnostic error is to use subjective improvement after immunotherapy as proof that CIDP was present.

This is circular reasoning.

Pain, fatigue and nonspecific sensory symptoms can fluctuate independently of demyelinating disease.

Objective measures should therefore be recorded before treatment and at predetermined intervals.

Useful measures include:

INCAT disability score;
I-RODS;
MRC sum score;
grip strength;
timed walk;
timed up-and-go;
quantitative sensory testing where appropriate;
patient-reported quality-of-life measures.

A genuine response should ideally demonstrate concordance across several domains.

Special Considerations in Older Adults

Age is important in both CIDP and post-COVID neurological disease.

Older patients are more likely to have:

diabetes;
renal dysfunction;
monoclonal gammopathy;
spinal stenosis;
vitamin deficiency;
vascular disease;
medication toxicity;
polypharmacy.

These conditions may mimic or coexist with CIDP.

Older patients may also have less complete neurological recovery because prolonged demyelination can produce secondary axonal degeneration and because peripheral nerve regenerative capacity declines with age.

Treatment risks are also greater.

For example, corticosteroids can worsen glucose control, while IVIg can cause volume-related complications, thrombotic events and, rarely, renal dysfunction depending on formulation and patient characteristics.

Treatment must therefore be individualized.

CIDP and Diabetes

The coexistence of diabetes and CIDP deserves special emphasis.

Diabetic distal symmetric polyneuropathy is overwhelmingly more common than CIDP.

The danger is twofold:

CIDP may be incorrectly diagnosed because diabetic neuropathy produces nonspecific conduction slowing.
Genuine CIDP may be missed because progressive neurological deterioration is automatically attributed to diabetes.

The clinical pattern is crucial.

Prominent proximal weakness, rapid progression, generalized areflexia, marked motor involvement and convincing multifocal demyelination should increase suspicion for CIDP.

Conversely, a slowly progressive length-dependent sensory neuropathy with mild distal weakness and typical diabetic complications is more compatible with diabetic polyneuropathy.[30]

CIDP and Spinal Disease

Spinal pathology is another major confounder.

Lumbar stenosis, disc disease, spondylolisthesis and previous lumbar fusion can produce:

weakness;
sensory loss;
gait impairment;
reflex changes;
radicular pain.

However, structural spinal disease does not explain diffuse abnormalities in multiple peripheral nerves.

Conversely, CIDP does not explain focal dermatomal symptoms or clear mechanical compression.

In patients with both disorders, electrodiagnostic testing is particularly valuable.

Pathological Convergence: SARS-CoV-2, Endothelium, Immunity and Myelin

The most plausible unified model can be summarized as follows:

SARS-CoV-2 infection → innate immune activation → endothelial and microvascular injury → altered blood-nerve-barrier function → adaptive immune activation → autoreactive B/T-cell expansion → antibody/complement/macrophage-mediated injury → segmental demyelination → conduction failure → secondary axonal loss if untreated.

This model is not proven as a single linear pathway.

Rather, it represents a convergence of several independently supported biological processes.

The principal uncertainty concerns the transition from generalized post-infectious immune activation to the highly specific immune attack characteristic of CIDP.

Future research must therefore identify the missing intermediate step.

Research Priorities

Prospective epidemiology

The most important unanswered question is incidence.

Large population-based cohorts should compare CIDP incidence among:

SARS-CoV-2-infected individuals;
matched uninfected controls;
individuals infected before vaccination;
vaccinated and infected cohorts;
individuals with repeated infection.

Confounding by age, diabetes and healthcare utilization must be carefully controlled.

Phenotyping

Cases should undergo standardized:

neurological examination;
nerve-conduction testing;
CSF analysis where appropriate;
nerve ultrasound;
MRI;
antibody testing;
serum proteomics;
immune-cell profiling.

Viral persistence studies

Longitudinal tissue and blood studies should determine whether patients with post-COVID CIDP demonstrate persistent viral antigen more frequently than patients with uncomplicated recovery.

The distinction between RNA fragments and replication-competent virus is essential.

Immunoglobulin repertoire

High-throughput B-cell receptor sequencing and autoantibody profiling may reveal whether post-COVID CIDP represents:

ordinary CIDP triggered by infection;
a distinctive autoantibody-defined disease;
a heterogeneous mixture of immune phenotypes.

Genomics

Genome-wide association studies could determine whether host genetic variants increase susceptibility.

Viral whole-genome sequencing could determine whether particular lineages are disproportionately represented among post-COVID CIDP cases.

Biomarkers

An ideal biomarker would distinguish:

active CIDP;
treated/remission CIDP;
diabetic neuropathy;
post-COVID small-fibre neuropathy;
axonal neuropathy;
autoimmune nodopathy.

Candidate approaches include:

neurofilament light chain;
cytokine panels;
complement fragments;
autoantibodies;
proteomic signatures;
metabolomic profiles;
immune-cell phenotyping.

None currently has sufficient specificity to replace clinical and electrophysiological diagnosis.

The Importance of Neurofilament Light Chain

Neurofilament light chain (NfL) reflects axonal injury and has emerged as a promising biomarker across neurological diseases.

Its conceptual value in CIDP is substantial.

Demyelination without substantial axonal injury may be reversible. Persistent elevation of NfL could therefore signal ongoing axonal damage.

In post-COVID patients, however, elevated NfL may result from multiple neurological processes.

NfL should consequently be considered a marker of neuronal injury rather than a CIDP-specific diagnostic biomarker.

Could SARS-CoV-2 Produce a Distinct CIDP Phenotype?

This remains an open question.

One possibility is that post-COVID CIDP is phenotypically indistinguishable from ordinary CIDP.

Another is that SARS-CoV-2 disproportionately triggers particular variants, such as:

acute-onset CIDP;
sensory-predominant CIDP;
nodopathy;
multifocal CIDP;
small-fibre/autonomic overlap syndromes.

Current case numbers are insufficient to establish such patterns.

Published reports have included acute-onset cases, but ascertainment bias is substantial because unusual presentations are more likely to be reported.

Vaccination and CIDP

The question of vaccination requires careful separation from infection.

Rare cases of CIDP have been reported after SARS-CoV-2 vaccination.[33,34]

However, spontaneous CIDP occurs in the population, and temporal association alone cannot establish vaccine causality.

Furthermore, infection itself is a substantially more complex immunological exposure than vaccination.

The appropriate scientific approach is therefore to investigate both exposures within the same epidemiological framework rather than infer causation from case reports.

Importantly, the existence of rare post-vaccination cases does not establish that vaccination is a common cause of CIDP.

Long-term Prognosis

CIDP has a variable natural history.

Some patients experience a monophasic illness and eventually discontinue treatment. Others require long-term immunotherapy. Some experience repeated relapses.

A 2023 systematic review and meta-analysis of 21 studies involving 1199 patients found a pooled remission rate of approximately 41%, while approximately 47% had a good outcome without disability; approximately 8% were nonambulatory in pooled analyses.[35]

These figures emphasize both the treatability and potential seriousness of CIDP.

Prognosis depends upon:

age;
disease duration before treatment;
severity at treatment initiation;
degree of axonal loss;
phenotype;
treatment response;
comorbid disease;
relapse frequency.

The presence of secondary axonal degeneration is especially important.

A patient whose nerves remain predominantly demyelinated may improve dramatically once inflammation is suppressed. A patient with extensive axonal degeneration may experience only partial recovery despite complete immunological control.

Prognosis of Post-COVID CIDP

There are insufficient data to determine whether post-COVID CIDP has a better or worse prognosis than idiopathic CIDP.

Theoretically, an acute infectious trigger could produce a monophasic immune response that eventually resolves.

Alternatively, SARS-CoV-2 could initiate a self-sustaining autoimmune process that behaves indistinguishably from idiopathic CIDP.

Longitudinal studies are needed to determine whether post-COVID cases have different:

remission rates;
relapse rates;
treatment requirements;
antibody profiles;
axonal loss;
disability trajectories.

Until those studies are available, treatment decisions should be based on disease phenotype rather than presumed viral causation.

A Proposed Clinical Algorithm

A patient with neurological symptoms after COVID-19 should undergo the following conceptual evaluation.

Step 1: Establish the phenotype

Is the syndrome:

motor;
sensory;
sensorimotor;
autonomic;
small-fibre;
focal;
multifocal;
length-dependent;
proximal and distal?

Step 2: Establish chronology

Did symptoms evolve:

within days;
over several weeks;
over more than eight weeks;
in relapsing fashion?

Step 3: Examine objectively

Document strength, reflexes, vibration, proprioception and gait.

Step 4: Perform electrodiagnostic testing

Determine whether acquired demyelination is convincingly demonstrated.

Step 5: Exclude mimics

Evaluate diabetes, paraproteinemia, hereditary neuropathy, anti-MAG disease, nodopathy, vasculitis, amyloidosis, nutritional deficiency and structural disease.

Step 6: Use supportive investigations

Consider:

CSF;
MRI;
ultrasound;
antibody testing;
nerve biopsy in exceptional circumstances.

Step 7: Treat confirmed disease

Use guideline-supported therapy.

Step 8: Measure response objectively

Do not rely solely on subjective improvement.

Step 9: Reconsider the diagnosis when treatment fails

Failure of multiple appropriately delivered treatments should trigger diagnostic reassessment rather than automatic escalation of immunosuppression.

Common Diagnostic Errors

Error 1: “It happened after COVID, therefore it is CIDP.”

Temporal association is not diagnostic.

Error 2: “The EMG says demyelinating, therefore it is CIDP.”

Electrophysiological demyelination has numerous mimics.

Error 3: “The patient has diabetes, therefore it is diabetic neuropathy.”

Diabetes does not exclude CIDP.

Error 4: “The patient improved after IVIg, therefore the diagnosis is confirmed.”

Placebo effects, nonspecific immune modulation and spontaneous fluctuation can confound treatment response.

Error 5: “MRI shows nerve-root enhancement, therefore CIDP is proven.”

Root enhancement is supportive, not pathognomonic.

Error 6: “The patient was initially diagnosed with GBS, so later deterioration is another GBS episode.”

Repeated deterioration beyond eight weeks should prompt evaluation for acute-onset CIDP.

Error 7: “Normal CSF protein excludes CIDP.”

CSF findings are supportive rather than obligatory.

Therapeutic Research Agenda

The next generation of CIDP trials should move beyond broad immunosuppression.

Potential therapeutic classes include:

FcRn inhibitors

These reduce circulating IgG and are already clinically validated by the ADHERE trial.[31,32]

Complement inhibitors

Complement blockade is biologically attractive in antibody-mediated neuropathies.

B-cell depletion

Rituximab and next-generation anti-CD19 therapies may benefit antibody-defined subgroups.

Plasma-cell targeting

In severe antibody-mediated disease, therapies targeting antibody-producing plasma cells may eventually become relevant.

Antigen-specific tolerance

A long-term goal would be suppression of pathogenic immunity without generalized immunosuppression.

Precision immunology

The future of CIDP treatment may involve matching therapy to immunological subtype rather than treating all patients identically.

Theoretical Implications for Post-COVID Neurology

The relationship between SARS-CoV-2 and CIDP illustrates a broader principle in post-infectious medicine.

An infection need not remain present to produce persistent disease.

The initiating pathogen can function as an immunological event that changes the host’s immune state.

This model is not unique to COVID-19. Numerous infections can precede autoimmune neurological disease.

What makes SARS-CoV-2 unusual is the enormous number of infections, the broad tissue effects of the virus and the frequency with which persistent symptoms have been recognized.

The challenge is therefore to distinguish true post-infectious disease from coincidental disease occurring after a common infection.

Limitations of the Current Evidence

Several limitations constrain conclusions.

First, most reports of post-COVID CIDP are case reports or small series.

Second, publication bias favors unusual cases.

Third, diagnostic criteria have evolved.

Fourth, many early reports predated contemporary EAN/PNS criteria.

Fifth, electrophysiological abnormalities may be difficult to interpret in patients with diabetes, critical illness or pre-existing neuropathy.

Sixth, SARS-CoV-2 infection is now extraordinarily common, making temporal associations particularly vulnerable to coincidence.

Seventh, there is insufficient longitudinal immunological profiling.

Eighth, vaccination and infection frequently coexist, complicating causal attribution.

Ninth, long COVID itself encompasses heterogeneous neurological syndromes that can be mistaken for CIDP.

Finally, there is no validated biomarker demonstrating that a particular case of CIDP was caused by SARS-CoV-2.

Strengths of the Evidence for Biological Plausibility

Despite these limitations, the biological case is substantial.

SARS-CoV-2 can:

produce profound immune activation;
alter B- and T-cell responses;
activate complement;
injure endothelium;
disrupt microvascular function;
alter barrier permeability;
induce autoantibodies in subsets of patients;
produce persistent antigenic material in some individuals;
cause recognized immune-mediated neurological syndromes.

CIDP can involve:

T-cell-mediated inflammation;
macrophage-mediated demyelination;
pathogenic antibodies;
complement;
nodal/paranodal immune injury;
blood-nerve-barrier dysfunction.

The convergence is therefore biologically coherent.

What remains missing is sufficiently strong epidemiological evidence and a disease-specific mechanistic signature.

Toward a Causal Model

A useful causal framework is:

SARS-CoV-2 exposure

↓

Viral replication and innate immune activation

↓

Cytokine, interferon, complement and endothelial responses

↓

Altered blood-nerve-barrier function and antigen presentation

↓

B-cell/T-cell activation

↓

Molecular mimicry and/or epitope spreading and/or loss of immune tolerance

↓

Antibodies or cellular responses directed against myelin, Schwann-cell or nodal/paranodal structures

↓

Macrophage-mediated demyelination and conduction failure

↓

Clinical weakness, sensory loss, areflexia and gait dysfunction

↓

If persistent: secondary axonal degeneration

This should be regarded as a research framework rather than an established sequence.

Long-term Outlook

The outlook for CIDP has improved substantially.

The disease was historically associated with chronic disability, prolonged corticosteroid exposure and repeated plasma exchange. IVIg transformed management. Subcutaneous immunoglobulin improved long-term administration. The identification of nodal antibodies has revealed biologically distinct subgroups. FcRn blockade now offers a mechanistically targeted therapy with randomized evidence of reduced relapse.

These advances suggest that the future of CIDP is likely to be one of precision neuroimmunology.

For patients whose CIDP follows SARS-CoV-2, this future is particularly relevant.

The key question may eventually become not whether a patient “has post-COVID CIDP,” but rather:

What immune mechanism is operating in this patient’s CIDP, and which therapy most precisely suppresses it?

SARS-CoV-2 may serve as an initiating trigger without remaining the principal driver of disease.

That distinction could fundamentally change treatment.

Conclusions

SARS-CoV-2 infection has unquestionably expanded the spectrum of neurological disease encountered in clinical practice. Peripheral nervous-system manifestations include a broad range of disorders, from small-fibre neuropathy and dysautonomia to GBS, cranial neuropathies, myositis and inflammatory demyelinating neuropathies.[1-4]

CIDP is an especially important possibility because it is a potentially disabling but treatable disorder.

The available literature supports several conclusions.

First, CIDP can occur after SARS-CoV-2 infection.

Second, acute-onset CIDP may initially be indistinguishable from GBS and should be reconsidered when neurological deterioration continues or recurs beyond the expected temporal course of GBS.

Third, SARS-CoV-2 provides a biologically plausible immune trigger through mechanisms involving inflammation, endothelial injury, complement, blood-nerve-barrier dysfunction and adaptive immune dysregulation.

Fourth, current evidence does not establish that SARS-CoV-2 directly infects peripheral nerves as the principal cause of CIDP.

Fifth, temporal association is insufficient to establish causation because CIDP occurs independently of COVID-19 and SARS-CoV-2 exposure is now ubiquitous.

Sixth, the diagnosis should be based on a compatible clinical phenotype, objective electrodiagnostic evidence of acquired demyelination and appropriate exclusion of mimics, with CSF, MRI, ultrasound, antibody studies and treatment response used as supportive evidence.[5-8]

Seventh, IVIg, corticosteroids and plasma exchange remain the foundational therapies, while subcutaneous immunoglobulin provides an important maintenance strategy.

Eighth, FcRn inhibition represents a major advance. The ADHERE randomized trial demonstrated a substantial reduction in relapse risk with subcutaneous efgartigimod, and the therapy has subsequently entered clinical practice for adult CIDP.[31,32]

Finally, the central unanswered scientific question is whether SARS-CoV-2 merely precedes a conventional CIDP phenotype in some patients or whether it creates a biologically distinct subtype of inflammatory neuropathy.

Answering that question will require prospective cohorts, rigorous epidemiology, standardized electrodiagnostics, serial immune profiling, viral persistence studies, autoantibody characterization, host and viral genomics, and adequately powered therapeutic trials.

For the clinician, the practical message is straightforward: post-COVID neurological symptoms should neither be dismissed as nonspecific long COVID nor automatically labeled CIDP. The correct approach is objective neurological phenotyping followed by disciplined electrodiagnostic and laboratory evaluation. When true CIDP is identified, timely disease-modifying treatment remains essential because preventing secondary axonal degeneration offers the best opportunity for meaningful long-term neurological recovery.

Key Messages for Clinical Practice

CIDP is a specific immune-mediated demyelinating neuropathy, not a synonym for post-COVID neuropathy.
SARS-CoV-2 can temporally precede CIDP, but current evidence is insufficient to establish that infection causes CIDP in the population.
A patient initially diagnosed with GBS who deteriorates after eight weeks should be evaluated for acute-onset CIDP.
Nerve-conduction studies are central to diagnosis.
CSF protein elevation, MRI nerve-root enhancement and nerve enlargement on ultrasound are supportive rather than diagnostic.
Diabetes, paraproteinemia, hereditary neuropathy, anti-MAG neuropathy, autoimmune nodopathy and structural spinal disease are important mimics.
IVIg, corticosteroids and plasma exchange remain evidence-based first-line therapies.
Subcutaneous immunoglobulin is an important maintenance treatment.
FcRn blockade with efgartigimod represents an important new targeted treatment strategy.
Early diagnosis matters because prolonged demyelination can lead to secondary axonal degeneration and irreversible disability.

References / Footnotes

Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767-783.
Dalakas MC. Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2020;7.
Costello F, Dalakas MC. Neurological complications and considerations in COVID-19 vaccine recipients. Ann Neurol. 2021;89:1029-1037.
Finsterer J, Scorza FA, Scorza CA. SARS-CoV-2 and peripheral neuropathy. Acta Neurol Scand. 2021;143:370-373.
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force—second revision. J Peripher Nerv Syst. 2021;26:242-268.
Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;90:981-987.
Bright RJ, Wilkinson J, Coventry BJ. Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. BMC Neurol. 2014;14:26.
Rajabally YA, Mahdi-Rogers M, Gosalakkal JA, et al. Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2022.
Samakoush MA, Davoodi L, Khademian M, Kargar-Soleimanabad S, Abedini MA. New-onset chronic inflammatory demyelinating polyradiculoneuropathy after COVID-19 infection: a case report. Ann Med Surg. 2023.
De Sanctis P, et al. Acute-onset chronic inflammatory demyelinating polyneuropathy complicating SARS-CoV-2 infection and Ad26.COV2.S vaccination: report of two cases. 2022.
Post-COVID-19 chronic inflammatory demyelinating polyneuropathy: a case report of diagnosis and management. 2026.
Joint Task Force of the European Academy of Neurology and Peripheral Nerve Society. Guideline on diagnosis and treatment of CIDP. 2021.
Naqvi SK, et al. A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program. Future Virol. 2022.
V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155-170.
Chen B, Farzan M, Choe H. SARS-CoV-2 spike protein: structure, viral entry and variants. Nat Rev Microbiol. 2025;23:455-468.
Bohan D, Van Der Veken L, Rambaud C, et al. Neuropilin-1 and neuropilin-2 as SARS-CoV-2 entry factors. J Virol. 2021.
Lee MH, Perl DP, Nair G, et al. Microvascular injury in the brains of patients with COVID-19. N Engl J Med. 2021;384:481-483.
Stengel H, Vural A, O’Connor KC. The emerging role of antibodies in CIDP and autoimmune nodopathies. Curr Opin Neurol. 2021.
Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133-146.
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19: pathogenesis and clinical implications. Clin Infect Dis. 2021;73: e3372-e3380.
Mechanistic insights into Long Covid: viral persistence, immune dysregulation and multi-organ dysfunction. 2025.
Intestinal barrier compromise, viral persistence and immune dysregulation converge on neurological sequelae in Long COVID. 2026.
Dalakas MC. Pathogenesis and treatment of immune-mediated neuropathies. Neurology. 2015.
Gausmann KM, May RA, Sichtermann T, et al. Magnetic resonance imaging of nerve roots in the diagnosis of CIDP: systematic review and meta-analysis. Eur J Neurol. 2026;33.
Heiling B, Kneer K, He W, et al. Nerve ultrasound helps to distinguish CIDP patients with diabetes from patients with diabetic polyneuropathy. Sci Rep. 2024;14:30504.
Rajabally YA, Briani C. Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management. J Neurol Neurosurg Psychiatry. 2024.
Paraproteinemic neuropathies. Muscle Nerve. 2024.
Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment-related fluctuations. Neurology. 2005;65:138-140.
Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology. 2010.
Dunnigan SK, Ebadi H, Breiner A, et al. The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with diabetes. Nat Rev Neurol. 2017.
Allen JA, Lin J, Basta I, et al; ADHERE Study Group. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2024;23:1013-1024.
US Food and Drug Administration. FDA approves treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults: efgartigimod alfa and hyaluronidase-qvfc. 2024.
Piccolo G, et al. Chronic inflammatory demyelinating polyneuropathy after SARS-CoV-2 vaccination: update of the literature and patient characterization. Immunol Res. 2023.
Bahramy MA, Hashempour Z, Shahriarirad R. Chronic inflammatory demyelinating polyneuropathy following COVID-19 vaccination: a case report and literature review. BMC Neurol. 2024;24:262.
Al-Zuhairy A, Jakobsen J. Outcome in chronic inflammatory demyelinating polyneuropathy: a systematic review and meta-analysis. Muscle Nerve. 2023;68:388-396.
Chronic inflammatory demyelinating polyneuropathy and variants. 2025.
Chronic inflammatory demyelinating polyneuropathy: a narrative review of a systematic diagnostic approach to avoid misdiagnosis. 2025.
Updated diagnosis and treatment for chronic inflammatory demyelinating polyradiculoneuropathy based on the EAN/PNS guideline 2021. 2024.
French recommendations for the management of adult and pediatric chronic inflammatory demyelinating polyradiculoneuropathy. 2022.
New chronic inflammatory demyelinating polyneuropathy/Guillain-Barré syndrome guidelines: impact on clinical practice. 2024.
COVID-19 and the peripheral nervous system: a 2-year review from the pandemic to the vaccine era. 2022.
Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain. 2021.
SARS-CoV-2 infection in the central and peripheral nervous system-associated morbidities and their potential mechanism. 2021.
Neuropathogenesis of severe acute respiratory syndrome coronavirus 2. 2021.
Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022.
SARS-CoV-2: from its discovery to genome structure, transcription and replication. 2021.
Mutations in SARS-CoV-2: insights on structure, variants, vaccines and biomedical interventions. 2022.
Mutations in the genome of SARS-CoV-2: implications for COVID-19 severity and progression. 2022.
Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. 2011.
Current therapeutic options for CIDP and emerging targeted treatments. The contemporary treatment literature supports IVIg, corticosteroids and plasma exchange as established therapies while newer FcRn-directed approaches expand the therapeutic armamentarium.[5-7,31,32]